ReviewDrug design, development and therapy2018

Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas.

Jun Gong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.